Kerala Ayurveda issues Rs. 40 Crore Series A NCDs via private placement
BOARD
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 25 Mar 2026, 12:31 PM IST · BSE ID: 7b335588-6f61-40dd-8440-5fa8cf68ba40
View Original BSE Filing (PDF)
💡
In Simple Terms
Kerala Ayurveda borrowed Rs. 40 Crore through debt instruments at 12% interest, secured by factory assets, repayable over 10 years after 2-year moratorium.
🤖 AI Summary
- Board approved issuance of 4,000 Series A NCDs worth Rs. 40,00,00,000 on private placement basis
- Each debenture: Rs. 1,00,000 face value, 12% p.a. interest on reducing balance, quarterly payment
- Allotment within 1 month; 24-month moratorium then 32 quarterly instalments for repayment
- First charge on industrial property — factory land, building, plant & machinery as security
- Borrowing within shareholder limits approved 22 August 2025 under Companies Act Section 180(1)(c)
🔢 Key Numbers — exact figures from BSE filing, not rounded
Total debenture amount
Rs. 40,00,00,000 (Rupees Forty Crores only)
Number of NCDs
4,000 Series A unlisted secured redeemable Non-Convertible Debentures
Face value per NCD
Rs. 1,00,000 (Rupees One Lakh only)
Interest rate
12% p.a. on reducing balance
Payment frequency
Quarterly interest; moratorium 24 months then 32 quarterly principal instalments
Allotment timeline
Within 1 month from board approval (25 March 2026)
Security
First charge on factory land, building, plant & machinery
🏢 How This Affects the Company
Rs. 40,00,00,000 debt added to balance sheet. Interest outgo: Rs. 4.80 Crore annually (year 1, on full amount at 12%), declining as principal reduces. Debt servicing begins in Q3 FY28.
Factory assets (land, building, plant & machinery) encumbered by first charge — restricts sale or further pledging of these assets.
Asset encumbrance limits operational flexibility. Quarterly principal repayment of Rs. 1.25 Crore (approx.) from Q3 FY28 onwards creates fixed cash outflow obligation.
👥 What This Means For Shareholders
✅
Action Required
No action required. Board decision complies with prior shareholder approval dated 22 August 2025.
👤
Who Is Affected
All equity shareholders. Debt increases financial leverage and interest burden, reducing earnings available for dividends. No dilution of share capital.
🔍
Management Signal
Management prioritizes debt financing over equity to preserve shareholder ownership; signals confidence in debt service capacity from operations.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
NCD allotment completion filing — confirm allotment within 1 month of 25 March 2026
Q1 FY27 results — verify debt position in balance sheet and first quarter interest expense recognition
Credit ratings — check if rating agency assigns NCD rating; monitor downgrade risk if leverage spikes
MEDIUM RISK
💡 Investor Takeaway
Kerala Ayurveda raised Rs. 40,00,00,000 in debt via 4,000 secured NCDs at 12% p.a. interest. Allotment within 1 month; 24-month moratorium then 32 quarterly principal repayments. First charge on factory assets. Borrowing within August 2025 shareholder approval.
⚖️ Strengths & Concerns
✅ Positives
- Long tenure (10 years) and extended moratorium (24 months) provides repayment flexibility and reduces near-term cash pressure.
- Interest cost at 12% p.a. on reducing balance is transparent; quarterly payment schedule aids cash flow forecasting.
⚠️ Concerns
- First charge on factory assets restricts borrowing capacity and operational flexibility for asset-based financing.
- 32 quarterly instalments from month 25 create fixed Rs. 1.25 Crore+ quarterly cash obligation; earnings must sustain repayment.